MFDS Publishes Guide to the Use of AI in Drug Development
The Ministry of Food and Drug Safety (MFDS) announced on June 28th the publication of the "Guide to the Use of Artificial Intelligence (AI) in Drug Development," which presents considerations for the application of AI technology from both technical and ethical perspectives, in response to the increasing use of AI in drug development.
This guide specifically outlines the potential applications of AI in various stages of drug development, including candidate discovery, non-clinical trials, and clinical trials. It also provides guidance on considerations to be taken into account when using AI.
Notably, the use of AI in drug development can improve time, cost, and efficiency, as well as enable the safe and effective design of non-clinical trials and clinical trials. However, since AI inherently predicts results based on data, ensuring the quality and reliability of the data is critically important.
The MFDS expects that this guide will help in understanding drug development using AI and announced that it plans to actively support AI-based drug development and commercialization based on regulatory science expertise in the future.
CONTACT US
📧 forest.lee@gca-kr.com
